Inhibition of PCSK9 enhances the anti-hepatocellular carcinoma effects of TCR-T cells and anti-PD-1 immunotherapy
Weikang Xu, Minli Hu, Xinyu Lu, Yueqiong Lao, Na Ma, Yiyue Wang, Jing Li, Xingyuan Chen, Shiming Liu, Jing Liu, Wei‐Guo Zhu, Hui Yang
Abstract
T cells. LDLR deficiency was shown to impair cellular mTORC1 signaling and the anti-HCC function of CD8 T cells. On the basis of our findings in this study, we propose a potential metabolic intervention strategy that could be used to enhance the antitumor effects of immunotherapy for HCC.
Topics & Concepts
Hepatocellular carcinomaImmunotherapyT-cell receptorCancer researchCarcinomaMedicinePharmacologyImmunologyInternal medicineImmune systemT cellColorectal Cancer Treatments and StudiesCancer Immunotherapy and BiomarkersMelanoma and MAPK Pathways